Bloomberg Turnaround: How a CEO Doubled His Company's Share Price

The transcript discusses Zeneca's research facility in Sweden, emphasizing open communication among scientists to foster breakthroughs. It highlights AstraZeneca's new headquarters in Cambridge and the challenges faced due to expiring patents. In 2012, Pascal Soriot was appointed CEO to address these issues, leading to a strategic shift from cost-cutting to focusing on science and medicine development, resulting in a doubled share price. The turnaround was supported by IBM services.

What was the main reason for AstraZeneca's search for a new chief executive in 2011?

How did Pascal Soriot's appointment in 2012 impact AstraZeneca's share price?

What challenges did AstraZeneca face before the turnaround initiated by Pascal Soriot?

What was the focus of AstraZeneca's strategy after the reorganization and cost-cutting measures?

What role did IBM services play in AstraZeneca's turnaround?